CAMBRIDGE, Mass., March 25, 2021 /PRNewswire/ -- Akebia
Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company
with the purpose to better the lives of people impacted by kidney
disease, today announced that it will present data at the National
Kidney Foundation 2021 Spring Clinical Meetings (NKF SCM21), which
takes place virtually April 6-10,
2021.
Abstracts are now available online in the NKF SCM21 Abstract and
ePoster Gallery:
https://casehippo.com/spa/symposium/national-kidney-foundation-2021-spring-clinical-meetings/event/gallery/browser.
A poster, titled "A Drug-Drug Interaction Study of Vadadustat
Coadministered With Cyclosporine, a P-gp Inhibitor, and Digoxin, a
P-gp Substrate" (Poster #171), will present Phase 1 clinical
research evaluating the effect of cyclosporine on vadadustat
exposure and the effect of vadadustat on the exposure of digoxin
(Dig). Vadadustat is Akebia's investigational oral
hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI),
which recently completed its global Phase 3 clinical development
program for the treatment of anemia due to chronic kidney disease
(CKD) in adult patients both on dialysis and not on dialysis.
Additional Akebia and Akebia-sponsored posters include:
- Quality of Life (QoL) and Healthcare Utilization (HRU) in a
Phase 4 Study of Ferric Citrate (FC) in Patients With
Non–Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Iron
Deficiency Anemia (IDA) (Poster #166)
- Predictors of ESA Use in the Non-Dialysis Dependent Chronic
Kidney Disease Population with Anemia (Poster #170)
In addition, Akebia and Otsuka America Pharmaceutical, Inc.,
have provided educational grant funding in support of the
educational session, titled "Treatment of CKD Related Anemia: The
Emerging Role of Hypoxia Inducible Factor Inhibitors," scheduled
for Thursday, April 8, 2021 at
12:30 p.m. ET. The session will
feature speakers:
- Jeffrey Berns, M.D., who will
serve as facilitator and present, "Pathophysiology CKD Anemia and
Current Management Strategies;"
- Volker Haase, M.D., who will
present, "Emerging Therapies for CKD Anemia;" and,
- Stephen Fishbane, M.D., who will
present, "Clinical Trials Update: HIF-PHI."
NKF SCM21 attendees can visit the Akebia virtual booth at
https://www.akebiavirtualexperience.com/.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is
a fully integrated biopharmaceutical company with the purpose to
better the lives of people impacted by kidney disease. The Company
was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more
information, please visit our website at www.akebia.com, which does
not form a part of this release.
About Vadadustat
Vadadustat is an oral
hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor
designed to mimic the physiologic effect of altitude on oxygen
availability. At higher altitudes, the body responds to lower
oxygen availability with stabilization of hypoxia-inducible factor,
which can lead to increased red blood cell production and improved
oxygen delivery to tissues. Vadadustat recently completed its
global Phase 3 development program for the treatment of anemia due
to CKD. Vadadustat is not approved by the U.S. Food and Drug
Administration (FDA) or any regulatory authority with the exception
of Japan's Ministry of Health,
Labour and Welfare (MHLW). In Japan, vadadustat is approved as a treatment
for anemia due to CKD in both dialysis-dependent and non-dialysis
dependent adult patients.
Investor Contact
Kristen K. Sheppard, Esq.
Ir@akebia.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-announces-poster-presentations-and-educational-symposium-at-national-kidney-foundation-2021-virtual-spring-clinical-meetings-301255231.html
SOURCE Akebia Therapeutics